Drugs that Inhibit Hepatitis C

MICROBIOLOGY AND IMMUNOLOGY ON-LINE

DRUGS THAT TARGET HEPATITIS C REPLICATION

NS3/4A serine protease inhibitor

Boceprevir - Merke (Brand name Victrelis) used in combination with peg-interferon a and ribavirin; withdrawn from market
Telaprevir - Johnson and Johnson/Vertex (Brand name Incivek) also used in combination with peg-interferon a and ribavirin; withdrawn from market
Simeprevir - Janssen (Brand name Olysio) also used in combination with peg-interferon a and ribavirin
Paritaprevir - AbbieVie (* +)
Grazoprevir - Merck (#)
Glecaprevir - AbbieVie (^)
Voxilaprevir - Gilead, marketed with Sofosbuvir and Velpatasvir as Epclusa

NS5A replication complex inhibitor

Velpatasvir - Gilead
Ledipasvir - Gilead (used in combination with Sofosbuvir under the brand name Harvoni)
Ombitasvir - AbbVie (* +)
Daclatasvir - Bristol-Myers Squibb (Brand name Daklinza, used in combination include Sofosbuvir, Ribivirin, and interferon)
Elbasvir - Merck (#)
Pibrentasvir - AbbieVie (^)

NS5B RNA polymerase inhibitor

Dasabuvir - AbbVie (*)
Sofosbuvir - Gilead (Brand name Sovaldi) used in combination with Ledipasvir under the brand name Harvoni; in combination with Voxilaprevir and Velpatasvir as Epclusa

* Ombitasvir, Paritaprevir and Ritonavir tablets are co-packaged with Dasabuvir tablets under the brand name: Viekira Pak. Ritonavir is a protease inhibitor that is used in HIV treatment
+ Ombitasvir, Paritaprevir and Ritonavir tablets are marketed as Technivie
# Elbasvir and Grazoprevir are marketed as Zepatier
^ Glecaprevir and Pibrentasvir are marketed as Mavyret

Many of these drugs in combination carry the warning that their use risks hepatitis B virus reactivation in co-infected patients